US Activist Hedge Fund Institutional SEC 13D 13G — October 16, 2026
Across the 50 filings, the dominant theme is passive and mid-sized institutional positioning: the large majority are Schedule 13G/13G-A disclosures by investment advisers, banks, and hedge funds reporting stakes in the 5-10% range, which carry limited near-term signal on their own. The more material developments cluster in a handful of event-driven situations: the Clear Channel Outdoor take-private at $2.43/share, Eli Lilly's 19.9% stake in TRex Bio alongside Pfizer's 7.2% position, PIMCO's 48.8% FreightCar America stake and the rights-plan termination agreement, Holcim's pending mandatory tender for Cementos Pacasmayo at roughly 50% ownership, and XCF Global's acquisition-driven control shift to EEME Energy. Insider and holder selling was concentrated and notable: Comstock (MAK Capital) sold roughly 1.0M shares as the price fell about 31%, Newegg's Tekhill sold on 31 of 32 trading days as the price fell from roughly $15.87 to $11.30, and Shah Capital's Novavax sale of 2.87M shares contrasted with accumulation elsewhere. Accumulation signals were clearer in Silvercrest (Equinox building a 10.3% stake), Funko (net purchases of about 50,000 shares), and CytoMed (chairman buying in the open market at about $0.86). Several filings reflect regulatory and structural housekeeping, notably Shah Capital's ADV-W withdrawal and its move from 13D to 13G across VEON and Novavax, and Vereniging Aegon's 40-for-1 conversion and buyback program, which add complexity but not direct price catalysts. Quantitative period-over-period data was sparse in these filings, so most conclusions rest on ownership levels and transaction prices rather than reported YoY or QoQ financial trends.